Entera Bio (ENTX) Stock Forecast, Price & News

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Entera Bio in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ENTX shares.
View ENTX analyst ratings or view top-rated stocks.

2 brokers have issued twelve-month price targets for Entera Bio's shares. Their ENTX share price forecasts range from $5.00 to $10.00. On average, they anticipate the company's share price to reach $7.50 in the next twelve months. This suggests a possible upside of 820.1% from the stock's current price.
View analysts price targets for ENTX or view top-rated stocks among Wall Street analysts.

Entera Bio's stock was trading at $0.73 at the beginning of the year. Since then, ENTX stock has increased by 11.7% and is now trading at $0.8151.
View the best growth stocks for 2023 here.

Entera Bio saw a decrease in short interest in May. As of May 15th, there was short interest totaling 37,600 shares, a decrease of 23.7% from the April 30th total of 49,300 shares. Based on an average daily trading volume, of 230,300 shares, the days-to-cover ratio is presently 0.2 days. Approximately 0.2% of the shares of the company are sold short.
View Entera Bio's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023.
View our ENTX earnings forecast.

Entera Bio Ltd. (NASDAQ:ENTX) released its quarterly earnings data on Friday, March, 31st. The company reported ($0.10) EPS for the quarter, beating the consensus estimate of ($0.12) by $0.02. The company earned $0.01 million during the quarter, compared to analyst estimates of $0.10 million. Entera Bio had a negative trailing twelve-month return on equity of 85.95% and a negative net margin of 9,754.48%.

Based on aggregate information from My MarketBeat watchlists, some companies that other Entera Bio investors own include Fulcrum Therapeutics (FULC), Cara Therapeutics (CARA), Gilead Sciences (GILD), Supernus Pharmaceuticals (SUPN), VIVUS (VVUS), Vaxart (VXRT), AbbVie (ABBV), Acasti Pharma (ACST) and Allena Pharmaceuticals (ALNA).

(ENTX) raised $11 million in an initial public offering on Thursday, June 28th 2018. The company issued 1,400,000 shares at a price of $8.00 per share. Maxim Group served as the underwriter for the IPO and Joseph Gunnar was co-manager.

Entera Bio trades on the NASDAQ under the ticker symbol "ENTX."

Shares of ENTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ENTX stock can currently be purchased for approximately $0.82.

Entera Bio (NASDAQ:ENTX) has a market capitalization of $23.47 million and generates $130,000.00 in revenue each year. The company earns $-13,070,000.00 in net income (profit) each year or ($0.40) on an earnings per share basis.

Entera Bio's mailing address is FIFTH FLOOR KIRYAT HADASSAH MINRAV BUILDING, JERUSALEM L3, 9112002. The official website for the company is www.enterabio.com. The company can be reached via phone at (722) 532-7151 or via email at investorrelations@enterabio.com.